AMPE Ampio Pharmaceuticals Inc.

0.43
+0.01  (+2%)
Previous Close 0.42
Open 0.42
Price To Book 14.28
Market Cap 67,979,278
Shares 158,644,757
Volume 254,684
Short Ratio 16.03
Av. Daily Volume 593,688
Stock charts supplied by TradingView

NewsSee all news

  1. Ampio Provides Update on AP-013 Phase III Clinical Trial and Annual Meeting Conference Call Number

    ENGLEWOOD, Colo., Dec. 4, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment (SPA) Phase III clinical trial titled 

  2. Ampio Provides Update on Continued Progress of AP-013 Phase III Clinical Trial and Manufacturing Facility

    ENGLEWOOD, Colo., Oct. 10, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment (SPA) Phase III clinical trial titled

  3. Ampio Retains Legal Counsel for Transaction Advisory Committee

    ENGLEWOOD, Colo., Sept. 18, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment (SPA) phase three clinical trial titled 

  4. Ampio Pharmaceuticals Updates Progress of SPA Clinical Trial

    ENGLEWOOD, Colo., Sept. 17, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) today announced the progress to date in the Company's special protocol assessment (SPA) phase three clinical trial

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

As of July 24, 2019 enrolment has reached approximately 30%.
Ampion
Osteoarthritis of the Knee
Phase 2b data released May 2015 did not meet endpoints
Optina
Diabetic Macula Edema

Latest News

  1. Ampio Provides Update on AP-013 Phase III Clinical Trial and Annual Meeting Conference Call Number

    ENGLEWOOD, Colo., Dec. 4, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment (SPA) Phase III clinical trial titled 

  2. Ampio Provides Update on Continued Progress of AP-013 Phase III Clinical Trial and Manufacturing Facility

    ENGLEWOOD, Colo., Oct. 10, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment (SPA) Phase III clinical trial titled

  3. Ampio Retains Legal Counsel for Transaction Advisory Committee

    ENGLEWOOD, Colo., Sept. 18, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment (SPA) phase three clinical trial titled 

  4. Ampio Pharmaceuticals Updates Progress of SPA Clinical Trial

    ENGLEWOOD, Colo., Sept. 17, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) today announced the progress to date in the Company's special protocol assessment (SPA) phase three clinical trial